---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-22-000037"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2022-10-19T23:59:59+00:00"
generated_at: "2026-06-23T02:39:16.511477+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Skye extends EHT deal outside date to Nov 15, receives $700K loan from EHT

## Summary
- Third Amendment extends outside date for acquisition of Emerald Health Therapeutics to November 15, 2022, subject to possible 15-day extension.
- EHT loans Skye $700,000 at 12% interest (reduces to 5% upon deal closing), due earlier of Oct 17, 2023 or Dec 31, 2022 if deal terminated.
- Proceeds from loan to be used for general working capital; waiver obtained from Emerald Health Sciences for incurrence of debt.
- Stockholders and Supreme Court of British Columbia have approved the arrangement; closing expected early to mid-November.

## SEC filing metadata
- accession: 0001516551-22-000037
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2022-10-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655122000037/0001516551-22-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655122000037/skye-20221014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-22-000037
- JSON: https://secwatch.observer/filing/0001516551-22-000037.json
- Plain text: https://secwatch.observer/filing/0001516551-22-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.